 TORRANCE, Calif. , April 26, 2022 PRNewswire -- Emmaus Life Sciences, Inc. OTCQX: EMMA, a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced participation in the following investor conferences in May: May 3-4: Q2 Investor Summit 2022. 